Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 20.07.2023 · 41 (21) · 3700-3711
DOI: 10.1200/jco.23.00774 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2023. Verfasst von Gregory J Riely und 24 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAF V600E/K -mutant metastatic melanoma. We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAF V600E -mutant metastatic non–small-cell lung cancer (NSCLC). METHODS In this ongoing, open-label, single-arm, phase II study (ClinicalTrials.gov identifier: NCT03915951 ), patients with BRAF V600E -mutant metastatic NSCLC received oral encorafenib 450 mg once daily plus binimetinib 45 mg twice daily in 28-day cycles. The primary end point was confirmed objective response rate (ORR) by independent radiology review (IRR). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival, time to response, and safety. RESULTS At data cutoff, 98 patients (59 treatment-naïve and 39 previously treated) with BRAF V600E -mutant metastatic NSCLC received encorafenib plus binimetinib. Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib. ORR by IRR was 75% (95% CI, 62 to 85) in treatment-naïve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively. DCR after 24 weeks was 64% in treatment-naïve and 41% in previously treated patients. Median PFS was NE (95% CI, 15.7 to NE) in treatment-naïve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients. The most frequent treatment-related adverse events (TRAEs) were nausea (50%), diarrhea (43%), and fatigue (32%). TRAEs led to dose reductions in 24 (24%) and permanent discontinuation of encorafenib plus binimetinib in 15 (15%) patients. One grade 5 TRAE of intracranial hemorrhage was reported. Interactive visualization of the data presented in this article is available at the PHAROS dashboard ( https://clinical-trials.dimensions.ai/pharos/ ). CONCLUSION For patients with treatment-naïve and previously treated BRAF V600E -mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands.
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- Winship Cancer Institute of Emory University, Atlanta, GA.
- MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Ernest Nadal, Michael Offin, Mariano Provencio, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan W Goldman, Daniel Morgensztern, Paul Wissel, Bruce E Johnson
Zitieren
APA
Riely, G. J., Smit, E. F., Ahn, M. J., Felip, E., Ramalingam, S. S., Tsao, A., Johnson, M., Gelsomino, F., Esper, R., Nadal, E., Offin, M., Provencio, M., Clarke, J., Hussain, M., Otterson, G. A., Dagogo-Jack, I., Goldman, J. W., Morgensztern, D., Alcasid, A., …, & Johnson, B. E. (2023). Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 41(21), 3700-3711. https://doi.org/10.1200/jco.23.00774
Vancouver
Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, et al. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2023;41(21):3700-3711. doi:10.1200/jco.23.00774
BibTeX
@article{Riely2023,
author = {Riely, Gregory J and Smit, Egbert F and Ahn, Myung-Ju and Felip, Enriqueta and Ramalingam, Suresh S and Tsao, Anne and Johnson, Melissa and Gelsomino, Francesco and Esper, Raymond and Nadal, Ernest and Offin, Michael and Provencio, Mariano and Clarke, Jeffrey and Hussain, Maen and Otterson, Gregory A and Dagogo-Jack, Ibiayi and Goldman, Jonathan W and Morgensztern, Daniel and Alcasid, Ann and Usari, Tiziana and Wissel, Paul and Wilner, Keith and Pathan, Nuzhat and Tonkovyd, Svitlana and Johnson, Bruce E},
title = {Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non–Small-Cell Lung Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {21},
pages = {3700--3711},
doi = {10.1200/jco.23.00774}
}
EUVIMED